239 related articles for article (PubMed ID: 26112458)
21. [Tyrosine kinase inhibitors for the treatment of papillary thyroid cancer].
Politti U
Clin Ter; 2014; 165(6):e452-63. PubMed ID: 25524205
[TBL] [Abstract][Full Text] [Related]
22. Off-label use of Sorafenib in patients with advanced thyroid carcinoma: Retrospective analysis of five cases.
Bugalho MJ
J Cancer Res Ther; 2016; 12(2):1084-7. PubMed ID: 27461704
[TBL] [Abstract][Full Text] [Related]
23. A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.
Sereno M; Moreno V; Moreno Rubio J; Gómez-Raposo C; García Sánchez S; Hernández Jusdado R; Falagan S; Zambrana Tébar F; Casado Sáenz E
Anticancer Drugs; 2015 Oct; 26(9):1004-7. PubMed ID: 26237499
[TBL] [Abstract][Full Text] [Related]
24. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
Ye X; Zhu Y; Cai J
J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib (Nexavar) for thyroid cancer.
Med Lett Drugs Ther; 2014 May; 56(1443):43-4. PubMed ID: 24869715
[No Abstract] [Full Text] [Related]
27. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib makes headway on metastatic thyroid cancer.
Cancer Discov; 2013 Jul; 3(7):OF2. PubMed ID: 23847363
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
30. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
Kawalec P; Malinowska-Lipień I; Brzostek T; Kózka M
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1303-1309. PubMed ID: 27734713
[TBL] [Abstract][Full Text] [Related]
31. Targeted therapies in advanced differentiated thyroid cancer.
Carneiro RM; Carneiro BA; Agulnik M; Kopp PA; Giles FJ
Cancer Treat Rev; 2015 Sep; 41(8):690-8. PubMed ID: 26105190
[TBL] [Abstract][Full Text] [Related]
32. Thyroid carcinoma, version 2.2014.
Tuttle RM; Haddad RI; Ball DW; Byrd D; Dickson P; Duh QY; Ehya H; Haymart M; Hoh C; Hunt JP; Iagaru A; Kandeel F; Kopp P; Lamonica DM; Lydiatt WM; McCaffrey J; Moley JF; Parks L; Raeburn CD; Ridge JA; Ringel MD; Scheri RP; Shah JP; Sherman SI; Sturgeon C; Waguespack SG; Wang TN; Wirth LJ; Hoffmann KG; Hughes M
J Natl Compr Canc Netw; 2014 Dec; 12(12):1671-80; quiz 1680. PubMed ID: 25505208
[TBL] [Abstract][Full Text] [Related]
33. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
Lin CI; Whang EE; Lorch JH; Ruan DT
Surgery; 2012 Dec; 152(6):1142-9. PubMed ID: 23158184
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer.
Hegazi M; Azadi A; Jain D; Redman R; Perez CA
Drugs Today (Barc); 2015 Dec; 51(12):689-94. PubMed ID: 26798849
[TBL] [Abstract][Full Text] [Related]
35. Discovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays.
Qiu YQ; Zhou J; Kang XS; Shen-Tu JZ; Ding LM; Tan FL; Guo J; Li LJ
Afr J Tradit Complement Altern Med; 2012; 9(3):431-9. PubMed ID: 23983378
[TBL] [Abstract][Full Text] [Related]
36. Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
Eisner F; Schaberl-Moser R; Gerger A; Samonigg H; Pichler M
Onkologie; 2013; 36(6):368-70. PubMed ID: 23774152
[TBL] [Abstract][Full Text] [Related]
37. State of the art of the therapeutic perspective of sorafenib against hematological malignancies.
Zauli G; Voltan R; Tisato V; Secchiero P
Curr Med Chem; 2012; 19(28):4875-84. PubMed ID: 22934770
[TBL] [Abstract][Full Text] [Related]
38. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.
Dadu R; Devine C; Hernandez M; Waguespack SG; Busaidy NL; Hu MI; Jimenez C; Habra MA; Sellin RV; Ying AK; Cote GJ; Sherman SI; Cabanillas ME
J Clin Endocrinol Metab; 2014 Jun; 99(6):2086-94. PubMed ID: 24628550
[TBL] [Abstract][Full Text] [Related]
39. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
Kim A; Widemann BC; Krailo M; Jayaprakash N; Fox E; Weigel B; Blaney SM
Pediatr Blood Cancer; 2015 Sep; 62(9):1562-6. PubMed ID: 26207356
[TBL] [Abstract][Full Text] [Related]
40. Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.
Mirantes C; Dosil MA; Eritja N; Felip I; Gatius S; Santacana M; Matias-Guiu X; Dolcet X
Eur J Cancer; 2016 Aug; 63():74-87. PubMed ID: 27288872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
